Autism Spectrum Disorders. Pervasive developmental disorders
Conditions
Interventions
Treatment - Drugs
The intervention group have been treated with risperidone (maximum dose 2mg ), is also treated with Flavonoid Quercetin . Dosing and titration of the drug individually, but the total dose of Flavonoi
Sponsors
Vice Chancellor for Research of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria: Of all patients with ASD, ranging in age from 3to 12years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test. The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of Autism. Timepoint: Previous the syudy, 6 weeks after study, 12 weeks after study. Method of measurement: CARS test,CGI test.;Response to treatment. Timepoint: Previous the syudy, 6 weeks after study, 12 weeks after study. Method of measurement: CARS test,CGI test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug's side effect. Timepoint: Previous the study, 6weeks after study, 12weeks after study. Method of measurement: Check list. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Narges Nejati Fard
Mashhad University of Medical Siences
Outcome results
None listed